International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

被引：0

作者：

Pablo A. Olivera

Stephane Zuily

Paulo G. Kotze

Veronique Regnault

Sameer Al Awadhi

Peter Bossuyt

Richard B. Gearry

Subrata Ghosh

Taku Kobayashi

Patrick Lacolley

Edouard Louis

Fernando Magro

Siew C. Ng

Alfredo Papa

Tim Raine

Fabio V. Teixeira

David T. Rubin

Silvio Danese

Laurent Peyrin-Biroulet

机构：

[1] Centro de Educación Médica e Investigaciones Clínicas (CEMIC),Gastroenterology Section, Department of Internal Medicine

[2] Centre Hospitalier Régional Universitaire de Nancy,Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases

[3] University of Lorraine,IBD outpatient clinics, Colorectal Surgery Unit

[4] INSERM,Department of Medicine

[5] DCAC,NIHR Biomedical Research Centre

[6] Catholic University of Paraná (PUCPR),Center for Advanced IBD Research and Treatment

[7] Gastroenterology Division,Department of Gastroenterology

[8] Rashid Hospital,Department of Gastroenterology

[9] Dubai Health Authority,Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science

[10] Imelda GI Clinical Research Center,Division of Internal Medicine and Gastroenterology

[11] Imelda General Hospital,Department of Gastroenterology

[12] University of Otago,IBD Center, Department of Gastroenterology

[13] University of Birmingham and University Hospitals NHS Foundation Trust,Department of Biomedical Sciences

[14] Kitasato University,Department of Gastroenterology and INSERM NGERE U1256

[15] Kitasato Institute Hospital,undefined

[16] CHU Liège University Hospital,undefined

[17] Centro Hospitalar São João,undefined

[18] The Chinese University of Hong Kong,undefined

[19] Fondazione Policlinico Universitario “A. Gemelli” IRCCS,undefined

[20] Catholic University of Rome,undefined

[21] Cambridge University Hospitals NHS Foundation Trust,undefined

[22] Gastrosaúde - IBD Clinic,undefined

[23] University of Chicago Medicine,undefined

[24] Inflammatory Bowel Disease Center,undefined

[25] Humanitas Clinical and Research Center - IRCCS,undefined

[26] Humanitas University,undefined

[27] Pieve Emanuele,undefined

[28] University Hospital of Nancy,undefined

[29] University of Lorraine,undefined

来源：

Nature Reviews Gastroenterology & Hepatology | 2021年 / 18卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as ‘fully agree’ or ‘mostly agree’ with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.

引用

页码：857 / 873

页数：16

共 299 条

[1] Ungaro R(2017)Ulcerative colitis Lancet 389 1756-1770
[2] Mehandru S(2020)Crohn’s disease Nat. Rev. Dis. Prim. 6 22-994
[3] Allen PB(2014)Extraintestinal manifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways Inflamm. Bowel Dis. 20 987-654
[4] Peyrin-Biroulet L(2019)Comorbidities in inflammatory bowel disease: a call for action Lancet Gastroenterol. Hepatol. 4 643-1213
[5] Colombel J-F(2015)Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing Inflamm. Bowel Dis. 21 1204-186
[6] Roda G(2007)Inflammation and coagulation in inflammatory bowel disease: the clot thickens Am. J. Gastroenterol. 102 174-1097.e6
[7] van Sommeren S(2021)Shedding light on hemostasis in patients with inflammatory bowel diseases Clin. Gastroenterol. Hepatol. 19 1088-469
[8] Argollo M(2020)Inflammatory bowel disease and the risk for cardiovascular disease: does all inflammation lead to heart disease? Trends Cardiovasc. Med. 30 463-2610
[9] Papa A(2004)Inflammatory markers and the risk of coronary heart disease in men and women N. Engl. J. Med. 351 2599-e640
[10] Danese S(2013)Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center J. Crohns Colitis 7 e635-475

← 1 2 3 4 5 6 7 8 9 10 →